Zacks Investment Research upgraded shares of Nephros (OTCMKTS:NEPH) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. They currently have $7.75 price target on the stock.
According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “
Separately, Taglich Brothers reaffirmed a speculative buy rating on shares of Nephros in a report on Wednesday, April 24th.
In other news, insider Daron Evans purchased 43,172 shares of the business’s stock in a transaction on Friday, June 14th. The shares were acquired at an average price of $0.60 per share, for a total transaction of $25,903.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders acquired 81,672 shares of company stock worth $72,598. Corporate insiders own 6.80% of the company’s stock.
Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Article: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.